SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder: a public health view. Ment Retard Dev Disabil Res Rev. 2002;8:162170.
  • 2
    Birleson P, Sawyer M, Storm V. The mental health of young people in Australia: child and adolescent component of the national survey – a commentary. Australas Psychiatry. 2000;8:358362.
  • 3
    Root RWI, Resnick RJ. An update on the diagnosis and treatment of attention-deficit/hyperactivity disorder in children. Prof Psychol Res Pract. 2003;34:3441.
  • 4
    Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 1996;35:9971008.
  • 5
    Colledge E, Blair RJR. The relationship in children between the inattention and impulsivity components of attention deficit and hyperactivity disorder and psychopathic tendencies. Pers Individ Diff. 2001;30:11751187.
  • 6
    Crowley TJ, Mikulich SK, MacDonald M, Young, SE, Zerbe GO. Substance-dependent, conduct-disordered adolescent males: severity of diagnosis predicts 2-year outcome. Drug Alcohol Depend. 1998;49:225237.
  • 7
    Biederman J. ADHD across the lifecycle. Biol Psychiatry. 1997;42(Suppl):146.
  • 8
    Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. Ment Retard Dev Disabil. 1999;5:243250.
  • 9
    Fossati A, Novella L, Donati D, Donini M, Maffei C. History of childhood attention deficit/hyperactivity disorder symptoms and borderline personality disorder: a controlled study. Compr Psychiatry. 2002;43:369377.
  • 10
    Rey JM, Morris-Yates A, Singh M, Andrews G, Steward GW. Continuities between psychiatric disorders in adolescents and personality disorders in young adults. Am J Psychiatry. 1995;152:895900.
  • 11
    Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: An overview. J Clin Psychiatry. 1998;59(Suppl 7):5058.
  • 12
    Warner-Rogers J, Taylor A, Taylor E, Sandberg S. Inattentive behavior in childhood: epidemiology and implications for development. J Learn Disabil. 2000;33:520536.
  • 13
    Barkley RA. Issues in the diagnosis of attention-deficit/hyperactivity disorder in children. Brain Dev. 2003;25:7783.
  • 14
    MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: changes in effectiveness and growth after the end of treatment. Pediatr. 2004;113:762769.
  • 15
    Swanson JM, Elliot GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46:10151027.
  • 16
    Molina BSG, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry. 2007;46:10281040.
  • 17
    Bradley JDD, Golden CJ. Biological contributions to the presentation and understanding of attention-deficit/hyperactivity disorder: a review. Clin Psychol Rev. 2001;21:907929.
  • 18
    Mann CA, Lubar JF, Zimmerman AW, Miler CA, Muenchen RA. Quantitative analysis of EEG in boys with attention-deficit-hyperactivity disorder: controlled study with clinical implications. Pediatr Neurol. 1992;8:3036.
  • 19
    Riccio CA, Hynd GW, Cohen MJ, Gonzalez JJ. Neurological basis of attention deficit hyperactivity disorder. Except Child. 1993;60:118124.
  • 20
    Richardson AJ. Clinical trials of fatty acid supplementation in ADHD. In: GlenAIM, PeetM, HorrobinDF, eds. Phospholipid Spectrum Disorders in Psychiatry and Neurology. Marius Press: Carnforth. 2003:529541
  • 21
    Curtis LT, Patel K. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): a review. J Altern Complement Med. 2008;14:7985.
  • 22
    Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants and attention deficit hyperactivity disorder in US children. Env Health Perspect. 2006;114:19041909.
  • 23
    Lecours AR, Mandujano M, Romero G. Ontogeny of brain and cognition: relevance to nutrition research. Nutr Rev. 2001;59(Suppl):S7S11.
  • 24
    Hetzel BS. Iodine and neuropsychological development. J Nutr. 2000;130(Suppl):S493S495.
  • 25
    Martinez M. Docosahexaenoic acid therapy in docosahexaenoic acid-deficient patients with disorders of peroxisomal biogenesis. Lipids. 1996;31(Suppl):S145S152.
  • 26
    Uauy R, Peirano P, Hoffman D, Mena P, Birch D, Birch E. Role of essential fatty acids in the function of the developing nervous system. Lipids. 1996;31(Suppl):S167S176.
  • 27
    Haller J. Vitamins and brain function. In: LiebermanHR, KanarekRB, PrasadC, eds. Nutritional Neuroscience. Taylor & Francis Group: Boca Raton. 2005:207233.
  • 28
    Sinn N, Howe PRC. Mental health benefits of omega-3 fatty acids may be mediated by improvements in cerebral vascular function. Biosci Hypotheses. 2008;1:103108.
  • 29
    Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15:619627.
  • 30
    Ward NI, Soulsbury KA, Zettel VH, Colquhoun ID, Bunday S, Barnes B. The influence of the chemical additive tartrazine on the zinc status of hyperactive children – a double-blind placebo-controlled study. J Nutr Environ Med. 1990;1:5157.
  • 31
    Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:181190.
  • 32
    Akhondzadeh S, Mohammadi M-R, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry. 2004;4:9
  • 33
    Bekaroglu M, Aslan Y, Gedik Y, et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry. 1996;37:225227.
  • 34
    Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on ADHD-related problems with attention and behavior. J Dev Behav Pediatr. 2007;28:8291.
  • 35
    Black MM. Micronutrient deficiencies and cognitive functioning. J Nutr. 2003;133(Suppl):S3927S3931.
  • 36
    Konofal E, Lecendreux M, Arnulf I, Mouren MC. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2004;158:11131115.
  • 37
    Oner O, Alkar IY, Oner P. Relation of ferritin levels with symptoms ratings and cognitive performance in children with attention deficit-hyperactivity disorder. Pediatr Int. 2008;50:4044.
  • 38
    Konofal E, Cortese S. Lead and neuroprotection by iron in ADHD. Environ Health Perspect. 2007;115:A398A399.
  • 39
    Konofal E, Cortese S, Marchand M, Mouren MC, Arnulf I, Lecendreux M. Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children. Sleep Med. 2007;8:711715.
  • 40
    Oner P, Dirik EB, Taner Y, Caykoylu A, Anlar O. Association between low serum ferritin and restless legs syndrome in patients with attention deficit hyperactivity disorder. Tohoku J Exp Med. 2007;213:269276.
  • 41
    Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiol. 1997;35:178180.
  • 42
    Konofal E, Cortese S, Lecendreux M, Arnulf I, Mouren MC. Effectiveness of iron supplementation in a young child with attention-deficit/hyperactivity disorder. Pediatrics. 2005;116:e732e734.
  • 43
    Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol. 2008;38:2026.
  • 44
    Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). Magnes Res. 1997;10:143148.
  • 45
    Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Magnes Res. 1997;10:149156.
  • 46
    Mousain-Bosc M, Roche M, Rapin J, Bali J-P. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. J Am Coll Nutr. 2004;23(Suppl):S545S548.
  • 47
    Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali J-P. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. Magnes Res. 2006;19:4652.
  • 48
    Salem N Jr, Litman B, Kim H-Y, Gawrisch K. Mechanisms of action of docosahexaenoic acid. Lipids. 2001;36:945959.
  • 49
    Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci. 2000;18:383399.
  • 50
    Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res. 2000;56:565570.
  • 51
    Hibbeln J, Ferguson TA, Blasbalg TL. Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation. Int Rev Psychiatry. 2006;18:107118.
  • 52
    Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids. 2001;36:937944.
  • 53
    Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids. 2006;75:259269.
  • 54
    Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypotheses. 1981;7:673679.
  • 55
    Burgess JR, Stevens LJ, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr. 2000;71:327330.
  • 56
    Chen J-R, Hsu S-F, Hsu C-D, Hwang L-H, Yang S-C. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem. 2004;15:467472.
  • 57
    Mitchell EA, Aman MG, Tubott SH, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr. 1987;26:406411.
  • 58
    Mitchell EA, Lewis S, Cutler DR. Essential fatty acids and maladjusted behaviour in children. Prostaglandins, Leukot Med. 1983;12:281287.
  • 59
    Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995;62:761768.
  • 60
    Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomised, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr. 2001;139:189196.
  • 61
    Stevens LJ, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. 2003;38:10071021.
  • 62
    Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder – a placebo-controlled double-blind study. Eur J Clin Nutr. 2004;58:467473.
  • 63
    Richardson AJ, Puri BK. A randomised double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:233239.
  • 64
    Richardson AJ, Montgomery P. The Oxford-Durham study: a randomised, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005;115:13601366.
  • 65
    Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006;18:155172.
  • 66
    Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukot Essent Fatty Acids. 2008;78:311326.
  • 67
    Ng F, Berk M, Dean O, Bush A. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;21:126.
  • 68
    Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002;40:158168.
  • 69
    Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol. 1998;32:509515.
  • 70
    Nishioka K, Hidaka T, Nakamura S, et al. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007;30:775780.
  • 71
    Greenblatt J. Nutritional supplements in ADHD. J Am Acad Child Adolesc Psychiatry. 1999;38:12091210.
  • 72
    Heimann SW. Pycnogenol for ADHD? J Am Acad Child Adolesc Psychiatry. 1999;38:357358.
  • 73
    Tenenbaum S, Paull JC, Sparrow EP, Dodd DK, Green L. An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). 2002;6:4960.
  • 74
    Trebatická J, Kopasová S, Hradečná Z, et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur Child Adolesc Psychiatry. 2006;15:329335.
  • 75
    Chovanová Z, Muchová J, Sivoňová M, et al. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radical Res. 2006;40:10031010.
  • 76
    Dvořáková M, Sivoňová M, Trebatická J, et al. The effect of polyphenolic extract from pine bark, Pycnogenol, on the level of glutathione in children suffering from attention deficit hyperactivity disorder (ADHD). Redox Report. 2006;11:163172.
  • 77
    Dvořáková M, Ježová D, Blažíček P, et al. Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): Modulation by a polyphenolic extract from pine bark (Pycnogenol). Nutr Neurosci. 2007;10:151157.
  • 78
    Feingold BF. Why is Your Child Hyperactive? 1975, New York: Random House.
  • 79
    Swaine A, Soutter V, Loblay R, Truswell AS. Salicylates, oligoantigenic diets, and behaviour. Lancet. 1985;2:4142.
  • 80
    Shaywitz BA, Goldenring JR, Wool RS. The effects of chronic administration of food colorings on activity levels and cognitive performance in developing rat pups treated with 6-hydroxydopamine. Neurobehav Toxicol. 1979;1:4147.
  • 81
    Goldenring JR, Batter DK, Shaywitz BA. Sulfanilic acid: behavioural change related to azo food dyes in developing rats. Neurobehav Toxicol Teratol. 1982;4:4349.
  • 82
    Kaplita PV, Triggle DJ. Food dyes: behavioural and neurochemical actions. Trends Pharmacol Sci. 1982;3:7071.
  • 83
    Kittler FJ, Baldwin DG. The role of allergic factors in the child with minimal brain dysfunction. Ann Allergy. 1970;28:203206.
  • 84
    Food and Drug Administration. Food ingredients and packaging. Summary of color additives listed for use in the United States in food, drugs, cosmetics, and medical devices. 2007: Available from: http://www.cfsan.fda.gov/~dms/opa-col2.html#table1A. Accessed July 25, 2008.
  • 85
    Weiss B. Food additives and environmental chemicals as sources of childhood behavior disorders. J Am Acad Child Psychiatry. 1982;21:144152.
  • 86
    Breakey J, Reilly C, Connell H. The role of food additives and chemicals in behavioral, learning, activity, and sleep problems in children. In: BranenAL, DavidsonM, SalminenS, ThorngateJHIII, eds. Food Additives. Second Edition. CRC Press. 2002:87100.
  • 87
    Cormier E. Diet and child behavior problems: fact or fiction? Pediatr Nurs. 2007;33:138143.
  • 88
    Arnold LE. Treatment alternatives for attention-deficit/hyperactivity disorder. J Atten Disord. 1999;3:3048.
  • 89
    Schab DW, Trinh NH-T. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials. J Dev Behav Pediatr. 2004;25:423434.
  • 90
    McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet. 2007;370:15601567.
  • 91
    Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. Omega-3 fatty acid status in attention–deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2006;75:299308.